Focus: Kura Oncology is a San Diego-based public biotech focused on small-molecule oncology therapeutics, currently in clinical-stage development with no approved products generating revenue.
Profile data last refreshed 42m ago · AI intelligence enriched 2mo ago
Stable — net -3 jobs in 30d
4 added, 7 removed. Backfill posture.
Kura is a promising early-stage oncology biotech with a focused pipeline and potential Phase 3 catalysts, but pre-revenue status and cash burn present execution and stability risks.
Help build intelligence for Kura Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Kura Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data TradingView
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations Investing.com
Kura says its menin inhibitor is preferred treatment for a 'handful' of payers - Endpoints News
Kura says its menin inhibitor is preferred treatment for a 'handful' of payers Endpoints News
8-K Filing: Kura Oncology, Inc. (KURA) (CIK 0001422143) — EX-99.1
EX-99.1
8-K Filing: Atrium Therapeutics, Inc. (CIK 0002093101) — EX-99.1
EX-99.1
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo